S06962 Summary:
BILL NO | S06962A |
  | |
SAME AS | SAME AS A10478 |
  | |
SPONSOR | HANNON |
  | |
COSPNSR | AKSHAR, AMEDORE, BOYLE, CROCI, GOLDEN, LARKIN, LATIMER, MARTINS, MURPHY, O'MARA, ORTT |
  | |
MLTSPNSR | |
  | |
Add §3216-a, Ins L | |
  | |
Provides for patient access to FDA approved abuse-deterrent technology to help combat opioid abuse. |
S06962 Actions:
BILL NO | S06962A | |||||||||||||||||||||||||||||||||||||||||||||||||
  | ||||||||||||||||||||||||||||||||||||||||||||||||||
03/10/2016 | REFERRED TO HEALTH | |||||||||||||||||||||||||||||||||||||||||||||||||
05/11/2016 | AMEND (T) AND RECOMMIT TO HEALTH | |||||||||||||||||||||||||||||||||||||||||||||||||
05/11/2016 | PRINT NUMBER 6962A | |||||||||||||||||||||||||||||||||||||||||||||||||
05/16/2016 | COMMITTEE DISCHARGED AND COMMITTED TO RULES | |||||||||||||||||||||||||||||||||||||||||||||||||
05/16/2016 | ORDERED TO THIRD READING CAL.851 | |||||||||||||||||||||||||||||||||||||||||||||||||
05/17/2016 | PASSED SENATE | |||||||||||||||||||||||||||||||||||||||||||||||||
05/17/2016 | DELIVERED TO ASSEMBLY | |||||||||||||||||||||||||||||||||||||||||||||||||
05/17/2016 | referred to insurance | |||||||||||||||||||||||||||||||||||||||||||||||||
06/16/2016 | substituted for a10478 | |||||||||||||||||||||||||||||||||||||||||||||||||
06/16/2016 | ordered to third reading rules cal.461 | |||||||||||||||||||||||||||||||||||||||||||||||||
06/16/2016 | passed assembly | |||||||||||||||||||||||||||||||||||||||||||||||||
06/16/2016 | returned to senate | |||||||||||||||||||||||||||||||||||||||||||||||||
11/16/2016 | DELIVERED TO GOVERNOR | |||||||||||||||||||||||||||||||||||||||||||||||||
11/28/2016 | VETOED MEMO.283 |
S06962 Committee Votes:
Go to topS06962 Floor Votes:
Yes
Abbate
Yes
Crespo
Yes
Gottfried
Yes
Lopez
Yes
Palumbo
Yes
Simon
Yes
Abinanti
Yes
Crouch
Yes
Graf
Yes
Lupardo
Yes
Paulin
Yes
Simotas
Yes
Arroyo
Yes
Curran
Yes
Gunther
Yes
Lupinacci
Yes
Peoples-Stokes
Yes
Skartados
Yes
Aubry
Yes
Cusick
Yes
Harris
Yes
Magee
Yes
Perry
Yes
Skoufis
Yes
Barclay
Yes
Cymbrowitz
Yes
Hawley
Yes
Magnarelli
Yes
Pichardo
Yes
Solages
Yes
Barrett
Yes
Davila
Yes
Hevesi
Yes
Malliotakis
Yes
Pretlow
Yes
Stec
Yes
Barron
Yes
DenDekker
Yes
Hikind
Yes
Markey
Yes
Quart
Yes
Steck
Yes
Benedetto
Yes
Dilan
Yes
Hooper
Yes
Mayer
Yes
Ra
Yes
Stirpe
Yes
Bichotte
Yes
Dinowitz
Yes
Hunter
Yes
McDonald
Yes
Raia
Yes
Tedisco
Yes
Blake
ER
DiPietro
Yes
Hyndman
Yes
McDonough
Yes
Ramos
Yes
Tenney
Yes
Blankenbush
Yes
Duprey
Yes
Jaffee
Yes
McKevitt
Yes
Richardson
Yes
Thiele
Yes
Brabenec
Yes
Englebright
Yes
Jean-Pierre
Yes
McLaughlin
Yes
Rivera
Yes
Titone
Yes
Braunstein
Yes
Fahy
Yes
Johns
Yes
Miller
Yes
Robinson
Yes
Titus
ER
Brennan
Yes
Farrell
Yes
Joyner
Yes
Montesano
Yes
Rodriguez
Yes
Walker
Yes
Brindisi
ER
Finch
ER
Katz
Yes
Morelle
Yes
Rosenthal
Yes
Walter
Yes
Bronson
Yes
Fitzpatrick
Yes
Kavanagh
Yes
Mosley
Yes
Rozic
Yes
Weinstein
Yes
Buchwald
Yes
Friend
Yes
Kearns
Yes
Moya
Yes
Russell
Yes
Weprin
Yes
Butler
Yes
Galef
ER
Kim
Yes
Murray
Yes
Ryan
Yes
Williams
Yes
Cahill
Yes
Gantt
Yes
Kolb
Yes
Nojay
Yes
Saladino
Yes
Woerner
Yes
Cancel
Yes
Garbarino
Yes
Lalor
Yes
Nolan
Yes
Santabarbara
Yes
Wozniak
Yes
Castorina
Yes
Giglio
Yes
Lavine
Yes
Oaks
Yes
Schimel
ER
Wright
Yes
Ceretto
Yes
Gjonaj
Yes
Lawrence
Yes
O'Donnell
Yes
Schimminger
Yes
Zebrowski
Yes
Colton
Yes
Glick
Yes
Lentol
Yes
Ortiz
Yes
Seawright
Yes
Mr. Speaker
Yes
Cook
Yes
Goldfeder
Yes
Lifton
Yes
Otis
Yes
Sepulveda
Yes
Corwin
Yes
Goodell
Yes
Linares
Yes
Palmesano
Yes
Simanowitz
‡ Indicates voting via videoconference
S06962 Text:
Go to top STATE OF NEW YORK ________________________________________________________________________ 6962--A IN SENATE March 10, 2016 ___________ Introduced by Sens. HANNON, AKSHAR, AMEDORE, BOYLE, CROCI, GOLDEN, LARKIN, LATIMER, MARTINS, MURPHY, ORTT -- read twice and ordered printed, and when printed to be committed to the Committee on Health -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee AN ACT to amend the insurance law, in relation to the use of abuse-det- errent technology for opioids as a mechanism for reducing abuse and diversion of opioid drugs The People of the State of New York, represented in Senate and Assem- bly, do enact as follows: 1 Section 1. The insurance law is amended by adding a new section 3216-a 2 to read as follows: 3 § 3216-a. Access to abuse-deterrent opioid medications. (a) An insur- 4 ance carrier or health plan shall provide coverage on its formulary, 5 drug list or other lists of similar construct for at least one abuse- 6 deterrent opioid analgesic drug product per opioid analgesic active 7 ingredient. 8 (1) Cost-sharing for brand name abuse-deterrent opioid analgesic drug 9 products covered pursuant to this section shall not exceed the lowest 10 cost-sharing level applied to brand name non-abuse deterrent opioid 11 drugs covered under the applicable health plan or policy. 12 (2) Cost-sharing for generic abuse-deterrent opioid analgesic drug 13 products covered pursuant to this section shall not exceed the lowest 14 cost-sharing level applied to generic non-abuse deterrent opioid drugs 15 covered under the applicable health plan or policy. 16 (3) An increase in patient cost-sharing or disincentives for prescri- 17 bers or dispensers shall not be allowed to achieve compliance with this 18 section. 19 (b) Any prior-authorization requirements or other utilization review 20 measures for opioid analgesics, and any service denials made pursuant 21 thereto, shall not require use of opioid analgesic drug products without 22 abuse-deterrent properties in order to access abuse-deterrent opioid 23 analgesic drug products. 24 (c) Definitions. As used in this section: EXPLANATION--Matter in italics (underscored) is new; matter in brackets [] is old law to be omitted. LBD14477-03-6S. 6962--A 2 1 (1) "Opioid analgesic drug product" means a drug in the opioid anal- 2 gesic drug class prescribed to treat moderate to severe pain or other 3 conditions, whether in immediate release or extended long acting release 4 form and whether or not combined with other drug substances to form a 5 single drug product or other dosage form. 6 (2) "Abuse deterrent opioid analgesic drug product" means a brand or 7 generic opioid analgesic drug product approved by the federal food and 8 drug administration with abuse-deterrence labeling claims indicating its 9 abuse-deterrent properties are expected to deter or reduce its abuse. 10 (3) "Cost-sharing" means any coverage limit, copayment, coinsurance, 11 deductible or other out-of-pocket patient expense requirements. 12 § 2. This act shall take effect on the one hundred twentieth day after 13 it shall have become a law, and shall apply to all policies and 14 contracts issued, renewed, modified, altered or amended on or after such 15 date.